Meridian Bioscience Revogene C. difficile assay recalled for declining performance and false-negative results
Meridian Bioscience's Revogene C. difficile diagnostic test (a lab assay used with the Revogene instrument) may show declining accuracy over time in certain lots. This could produce false-negative results, meaning the test might not detect C. difficile infection when it is present.
From the FDA notice · Read the official notice ↗
What to do
- Stop using affected lots: 410300U195, 410300U196, 410300U197, 410300U201
- Contact Meridian Bioscience for guidance on replacement or alternative testing
- Review recent test results from these lots with your lab director or healthcare provider
Is yours affected?
Compare your label or packaging with the recalled product.
- Product
- Revogene C. difficile, in vitro diagnostic assay intended for use with the Revogene instrument, Catalog Number 410300
- Sold in
- Nationwide
- Made for
- All ages (under 100 years)
Details
- Units affected
- 211 units
- Illnesses reported
- None reported
- Manufactured in
- 3471 River Hills Dr, Cincinnati, OH, United States
- Classification
- Class II
- Recall number
- Z-1019-2026
In the FDA's words
- Description
- Revogene C. difficile, in vitro diagnostic assay intended for use with the Revogene instrument, Catalog Number 410300 The affected lots show a decline in performance over time, which may lead to false-negative results. UDI-DI: 00840733102349; Lot Numbers: 410300U195, 410300U196, 410300U197, 410300U201 Distribution: US Nationwide distribution and the OUS country of Italy. Affected quantity: 211 units
- Hazard
- The affected lots show a decline in performance over time, which may lead to false-negative results.